call Toll Free (US/Canada): +1 866 658 6826 | call+1 425 320 4776 | call (UK): +44 1865 60 0662 | call (Ind): +91 9096278110 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Europe Genomic Cancer Panel And Profiling Market
Inquire Before Buying Request for Sample

Europe Genomic Cancer Panel And Profiling Market

Home Healthcare And Pharmaceutical Europe Genomic Cancer Panel And Profiling Market

Europe Genomic Cancer Panel and Profiling Market, By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others (CRISPR, Liquid Biopsy Technologies)); By Application (Clinical, Research); By End User (Hospitals, Clinical & Diagnostic Laboratories, Research & Academic Institutes, Others); By Region (Germany, United Kingdom, Italy, France, Spain, Belgium, Russia, The Netherlands, Rest of Europe), Trend Analysis, Competitive Landscape & Forecast, 2019–2030

  • Published Date: September 2024
  • Report ID: BWC24693
  • Available Format: PDF
  • Page: 240

Report Overview

Growing awareness about the benefits of genomic testing, increasing demand for personalized medicine, and favorable government policies to support the development of genomic medicine are expected to drive Europe Genomic Cancer Panel and Profiling Market during the forecast period between 2024 and 2030

Europe Genomic Cancer Panel and Profiling Market – Industry Trends & Forecast Report, 2030

Europe Genomic Cancer Panel and Profiling Market size was estimated at USD 2.62 billion in 2023. During the forecast period between 2024 and 2030, Europe Genomic Cancer Panel and Profiling Market size is projected to grow at a CAGR of 9.10% reaching a value of USD 4.71 billion by 2030. Prominent drivers of the market include increasing advancements in genomic technologies and the rising incidence of cancer across Europe. The increasing adoption of precision oncology, fueled by next-generation sequencing (NGS) technologies, is significantly enhancing early cancer detection and the use of personalized treatments. Additionally, growing awareness of targeted therapies, coupled with strong investments in research and development by key industry players, is propelling market growth. Collaborative efforts between biotech firms, academic institutions, and healthcare providers, alongside government funding to improve cancer research and healthcare infrastructure, are also fostering market expansion.

Europe Genomic Cancer Panel and Profiling Market

Genomic Cancer Panel and Profiling – Overview

Genomic cancer panels and profiling offer a cutting-edge approach to cancer detection by analyzing the genetic makeup of tumors before symptoms emerge. Their primary advantage lies in providing detailed genetic insights, enabling early diagnosis and the development of personalized treatment plans. The growing market for these technologies is driven by their potential to revolutionize cancer management, allowing healthcare professionals to identify specific genetic mutations and customize interventions for more effective care.

Europe Genomic Cancer Panel and Profiling Market

Growth Drivers

Favorable Policies Supporting the Development of Genomic Medicine

Favorable government policies play a pivotal role in supporting the development of genomic medicine, significantly boosting the growth of Europe Genomic Cancer Panel and Profiling Market. Initiatives such as Germany's genomDE strategy and the European Union's '1+ Million Genomes' (1+MG) project aim to enhance access to genomic medicine through robust legal frameworks and comprehensive data infrastructures. The genomDE strategy is set to launch a model project in 2024, which will facilitate accurate diagnoses and personalized treatments for rare and oncological diseases while emphasizing patient engagement, data security, and ethical considerations to foster public trust. Additionally, European governments are prioritizing genomic medicine to improve personalized healthcare and cancer treatment outcomes, supported by policies that include research funding, advancements in genomic testing technologies, and integration into healthcare systems. The 1+MG initiative, backed by 25 EU countries, the UK, and Norway, seeks to establish a comprehensive data infrastructure for genomic research, ensuring ethical practices are upheld. Its roadmap, spanning from 2018 to 2027, focuses on governance, data infrastructure, and public awareness, aimed at seamlessly integrating genomics into healthcare. The benefits of these initiatives extend to EU citizens through targeted therapies and enhanced diagnostics for cancer and other diseases, fostering collaboration among researchers and healthcare professionals. Ultimately, these favorable policies not only aim to revolutionize healthcare but also significantly contribute to the expansion of the genomic cancer panels and profiling market by ensuring that the necessary infrastructure and ethical frameworks are in place.

Challenges

High Costs associated with Genomic Testing

The substantial financial burden associated with genomic testing poses a significant barrier to the growth of European Genomic Cancer Panel and Profiling Market. Despite the promising potential of next-generation sequencing (NGS), the increased healthcare costs and limited reimbursement from public health systems hinder widespread adoption. While NGS can facilitate access to clinical trials, studies suggest that the associated costs do not consistently correlate with improved patient outcomes. To promote market expansion, it is imperative to develop more cost-effective solutions and establish clear guidelines for the utilization of genomic testing in clinical practice.

Impact of Escalating Geopolitical Tensions on Europe Genomic Cancer Panel and Profiling Market

Escalating geopolitical tensions among countries across regions could have a significant impact on the growth of Europe Genomic Cancer Panel and Profiling Market. Such tensions may disrupt supply chains and increase operational costs, creating uncertainty within the industry. Additionally, trade barriers and regulatory changes could limit access to essential genomic technologies, hindering research and development. Governments may prioritize national security over healthcare funding, potentially diverting resources away from critical genomic initiatives. This environment could slow innovation and reduce investment, ultimately affecting the availability and adoption of advanced genomic solutions vital for cancer diagnostics and personalized treatment.

Europe Genomic Cancer Panel and Profiling Market

Segmental Coverage

Europe Genomic Cancer Panel and Profiling Market – By Technology

By technology, Europe Genomic Cancer Panel and Profiling Market is divided into Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), and other (CRISPR and Liquid Biopsy Technologies) segments. The next-generation sequencing (NGS) segment holds the highest share in Europe Genomic Cancer Panel and Profiling Market by technology, due to its ability to deliver high-throughput, precise, and cost-effective genomic analysis. NGS enables comprehensive tumor profiling, facilitating personalized cancer treatment by identifying mutations and genetic alterations across various cancers. Its widespread adoption is driven by declining sequencing costs, technological advancements, and increasing oncology clinical applications. Additionally, guidelines from leading cancer organizations, such as ESMO, endorse NGS in routine clinical practice, further bolstering its dominant market position in Europe.

Europe Genomic Cancer Panel and Profiling Market – By Application

Based on application, Europe Genomic Cancer Panel and Profiling Market is bifurcated into Clinical and Research segments. The clinical segment holds a higher share in Europe Genomic Cancer Panel and Profiling Market by application. It can be attributed to the rising focus on personalized medicine, particularly in oncology, where healthcare providers are increasingly utilizing genomic profiling to tailor treatments to individual patients. Genomic cancer panels provide detailed genetic insights that guide the selection of targeted therapies, improving treatment outcomes and minimizing side effects. Advancements in sequencing technologies, such as next-generation sequencing (NGS), and supportive reimbursement policies have further facilitated the integration of genomic testing into routine clinical practice, enhancing its accessibility and adoption across Europe.

Europe Genomic Cancer Panel and Profiling Market Demand

Europe Genomic Cancer Panel and Profiling Market – By End User

Based on end user, Europe Genomic Cancer Panel and Profiling Market is divided into Hospitals, Clinical and Diagnostic Laboratories, Research and Academic Institutes, and other segments. 

Europe Genomic Cancer Panel and Profiling Market – By Country

The in-depth research report on the Europe Genomic Cancer Panel and Profiling Market covers the market in the region’s major countries including Germany, United Kingdom, Italy, France, Spain, Belgium, Russia, The Netherlands, and Rest of Europe. United Kingdom holds the highest share in Europe Genomic Cancer Panel and Profiling Market and is expected to maintain its dominance during the forecast period. United Kingdom’s leading position is supported by a robust regulatory framework and an advanced healthcare infrastructure, enabling the widespread adoption of genomic testing in cancer care. Regulatory bodies like the National Institute for Health and Care Excellence (NICE) have played a crucial role in guiding the use of genomic technologies. Additionally, initiatives like the Genomics England program have accelerated research and data collection, solidifying the UK's leadership in genomic cancer profiling.

Competitive Landscape

Major players operating in Europe Genomic Cancer Panel and Profiling Market include F. Hoffmann-La Roche Ltd, ARUP Laboratories, Agilent, Caris Life Sciences, Thermo Fisher Scientific, Danaher Corporation, Exact Sciences, EUCOPE, Guardant Health, Illumina, Merck & Co., Inc., and Novartis. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

  • In May 2024 - Guardant Health’s liquid biopsy test, Guardant360 CDx, obtained EU certification under the stricter In Vitro Diagnostic Regulation (IVDR) from TÜV SÜD Product Service. The test, which was the first FDA-approved blood test for profiling solid tumors, is now available in the European Union for patients with solid tumors. It also serves as a companion diagnostic to identify patients who may benefit from targeted therapies, particularly for non-small cell lung cancer and breast cancer.

  • In January 2023 - Burning Rock’s OverC Multi-Cancer Detection Blood Test (MCDBT) received Breakthrough Device Designation from the US FDA under the agency’s Breakthrough Devices Program. The designation is granted to innovative medical devices that offer improved diagnosis or treatment for life-threatening diseases like cancer. The program aims to accelerate the development, evaluation, and approval of these devices, ensuring faster access for patients and healthcare providers.

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2030

Base Year – 2023

Estimated Year – 2024

Forecast Period – 2024–2030

Facts Covered

USD Billion

Market Coverage

Germany, United Kingdom, Italy, France, Spain, Belgium, Russia, The Netherlands, Rest of Europe

Product/ Service Segmentation

Technology, Application, End User, Region

Key Players

F. Hoffmann-La Roche Ltd, ARUP Laboratories, Agilent, Caris Life Sciences, Thermo Fisher Scientific, Danaher Corporation, Exact Sciences, EUCOPE, Guardant Health, Illumina, Merck & Co., Inc., Novartis

 

By Technology

  • Next-Generation Sequencing (NGS)

  • Polymerase Chain Reaction (PCR)

  • Fluorescence In-Situ Hybridization (FISH)

  • Immunohistochemistry (IHC)

  • Others (CRISPR, Liquid Biopsy Technologies)

By Application

  • Clinical

  • Research

By End User

  • Hospitals

  • Clinical & Diagnostic Laboratories

  • Research & Academic Institutes

  • Others

By Country

  • Germany

  • United Kingdom

  • Italy

  • France

  • Spain

  • Belgium

  • Russia

  • The Netherlands

  • Rest of Europe

  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Executive Summary
  3.  Europe Genomic Cancer Panel and Profiling Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. Growing awareness of the benefits of genomic testing
        2. Increasing demand for personalized medicine
        3. Favorable government policies to support the development of genomic medicine
      2.  Restraints
        1. High costs associated with genomic testing
        2. Increasing concerns about data privacy and security
        3. Lack of standardized guidelines
      3. Opportunities
        1. Advancements in technology
        2. Expanding applications of genomic testing in various cancer types and stages
        3. Integration with electronic health records
      4. Challenges
        1. Securing reimbursement for genomic testing
        2. Addressing ethical concerns related to genomic testing
    3. Technological Advancements/Recent Developments
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4. Europe Genomic Cancer Panel and Profiling Market: Marketing Strategies
  5. Europe Genomic Cancer Panel and Profiling Market: Pricing Analysis
  6. Europe Genomic Cancer Panel and Profiling Market Overview
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share and Forecast
      1. By Technology
        1. Next-Generation Sequencing (NGS)
        2. Polymerase Chain Reaction (PCR)
        3. Fluorescence In-Situ Hybridization (FISH)
        4. Immunohistochemistry (IHC)
        5. Others (CRISPR, Liquid Biopsy Technologies)
      2. By Application
        1. Clinical
        2. Research
      3. By End User
        1. Hospitals
        2. Clinical & Diagnostic Laboratories
        3. Research & Academic Institutes
        4. Others
      4. By Region
        1. Germany
        2. United Kingdom
        3. Italy
        4. France
        5. Spain
        6. Belgium
        7. Russia
        8. The Netherlands
        9. Rest of Europe
  7. Germany Genomic Cancer Panel and Profiling Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Technology
      2. By Application
      3. By End User
  8. United Kingdom Genomic Cancer Panel and Profiling Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Technology
      2. By Application
      3. By End User
  9. Italy Genomic Cancer Panel and Profiling Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Technology
      2. By Application
      3. By End User
  10. France Genomic Cancer Panel and Profiling Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Technology
      2. By Application
      3. By End User
  11. Spain Genomic Cancer Panel and Profiling Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Technology
      2. By Application
      3. By End User
  12. Belgium Genomic Cancer Panel and Profiling Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Technology
      2. By Application
      3. By End User
  13. Russia Genomic Cancer Panel and Profiling Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Technology
      2. By Application
      3. By End User
  14. The Netherlands Genomic Cancer Panel and Profiling Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Technology
      2. By Application
      3. By End User
  15. Rest of Europe Genomic Cancer Panel and Profiling Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Technology
      2. By Application
      3. By End User
  16. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Europe Genomic Cancer Panel and Profiling Market Share Analysis, 2023
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
  17. Impact of Escalating Geopolitical Tensions on Europe Genomic Cancer Panel and Profiling Market
  18. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
    1. F. Hoffmann-La Roche Ltd
    2. ARUP Laboratories
    3. Agilent
    4. Caris Life Sciences
    5. Thermo Fisher Scientific
    6. Danher Corporation
    7. Exact Sciences
    8. EUCOPE
    9. Guardant Health
    10. Illumina
    11. Merck & Co., Inc.
    12. Novartis
    13. Other Prominent Players
  19. Key Strategic Recommendations
  20. Research Methodology
    1.    Qualitative Research
      1.  Primary & Secondary Research
    2.    Quantitative Research
    3.    Market Breakdown & Data Triangulation
      1.  Secondary Research
      2.  Primary Research
    4.    Breakdown of Primary Research Respondents, By Country
    5.    Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

 

List of Figures

 

Figure 1       Europe Genomic Cancer Panel and Profiling Market Segmentation

Figure 2       Europe Genomic Cancer Panel and Profiling Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2023

Figure 4       Europe Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019–2030

Figure 5       Europe Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019–2030

Figure 7       Europe Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019–2030

Figure 8       Europe Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019–2030

Figure 10     Europe Genomic Cancer Panel and Profiling Market Share, By Country, By Value, 2019–2030

Figure 11     Germany Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Figure 12     Germany Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Figure 13     Germany Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Figure 14     Germany Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Figure 15     United Kingdom Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Figure 16     United Kingdom Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Figure 17     United Kingdom Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Figure 18     United Kingdom Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Figure 19     Italy Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Figure 20     Italy Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Figure 21     Italy Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Figure 22     Italy Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Figure 23     France Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Figure 24     France Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Figure 25     France Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Figure 26     France Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Figure 27     Spain Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Figure 28     Spain Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Figure 29     Spain Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Figure 30     Spain Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Figure 31     Belgium Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Figure 32     Belgium Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Figure 33     Belgium Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Figure 34     Belgium Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Figure 35     Russia Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Figure 36     Russia Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Figure 37     Russia Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Figure 38     Russia Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Figure 31     The Netherlands Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Figure 32     The Netherlands Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Figure 33     The Netherlands Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Figure 34     The Netherlands Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Figure 43     Rest of Europe Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Figure 44     Rest of Europe Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Figure 45     Rest of Europe Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Figure 46     Rest of Europe Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

 

List of Tables

 

Table 1        Europe Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019–2030

Table 2        Europe Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019–2030

Table 3        Europe Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019–2030

Table 4        Europe Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019–2030

Table 5        Europe Genomic Cancer Panel and Profiling Market Share, By Country, By Value, 2019–2030

Table 6        Germany Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Table 7        Germany Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Table 8        Germany Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Table 9        Germany Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Table 10      United Kingdom Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Table 11      United Kingdom Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Table 12      United Kingdom Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Table 13      United Kingdom Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Table 14      Italy Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Table 15      Italy Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Table 16      Italy Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Table 17      Italy Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Table 18      France Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Table 19      France Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Table 20      France Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Table 21      France Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Table 22      Spain Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Table 23      Spain Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Table 24      Spain Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Table 25      Spain Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Table 26      Belgium Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Table 27      Belgium Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Table 28      Belgium Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Table 29      Belgium Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Table 30      Russia Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Table 31      Russia Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Table 32      Russia Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Table 33      Russia Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Table 34      The Netherlands Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Table 35      The Netherlands Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Table 36      The Netherlands Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Table 37      The Netherlands Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Table 38      Rest of Europe Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019−2030

Table 39      Rest of Europe Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019−2030

Table 40      Rest of Europe Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019−2030

Table 41      Rest of Europe Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019−2030

Table 42      F. Hoffmann-La Roche Ltd Company Overview

Table 43      F. Hoffmann-La Roche Ltd Financial Overview

Table 44      ARUP Laboratories Company Overview

Table 45      ARUP Laboratories Financial Overview

Table 46      Agilent Company Overview

Table 47      Agilent Financial Overview

Table 48      Caris Life Sciences Company Overview

Table 49      Caris Life Sciences Financial Overview

Table 50      Thermo Fisher Scientific Company Overview

Table 51      Thermo Fisher Scientific Financial Overview

Table 52      Danher Corporation Company Overview

Table 53      Danher Corporation Financial Overview

Table 54      Exact Sciences Company Overview

Table 55      Exact Sciences Financial Overview

Table 56      EUCOPE Company Overview

Table 57      EUCOPE Financial Overview

Table 58      Guardant Health Company Overview

Table 59      Guardant Health Financial Overview

Table 60      Illumina Company Overview

Table 61      Illumina Financial Overview

Table 62      Merck & Co., Inc. Company Overview

Table 63      Merck & Co., Inc. Financial Overview

Table 64      Novartis Company Overview

Table 65      Novartis Financial Overview

Market Segmentation

No data available
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: Europe Genomic Cancer Panel and Profiling Market size by value was estimated at USD 2.62 billion in 2023.
Ans: Europe Genomic Cancer Panel and Profiling Market is expected to grow at CAGR of 9.10% during the forecast period between 2024 and 2030.
Ans: By 2030, Europe Genomic Cancer Panel and Profiling Market size is forecast to reach a value of USD 4.71 billion.
Ans: The growth of Europe Genomic Cancer Panel and Profiling Market is primarily driven by the growing awareness of the benefits of genomic testing, increasing demand for personalized medicine, and favorable government policies to support the development of genomic medicine.
Ans: The clinical segment is expected to grow at a faster CAGR in Europe Genomic Cancer Panel and Profiling Market during the forecast period between 2024 and 2030.
Ans: Key players in Europe Genomic Cancer Panel and Profiling Market include F. Hoffmann-La Roche Ltd, ARUP Laboratories, Agilent, Caris Life Sciences, Thermo Fisher Scientific, Danaher Corporation, Exact Sciences, EUCOPE, Guardant Health, Illumina, Merck & Co., Inc., and Novartis.